IP Library › Granted Patent US 10,981,893
Granted Patent B2
US 10,981,893 · App. 15/741,191 · Granted Apr 20, 2021

Therapeutic inhibitory compounds

Inventors: Andrew McDonald (New York, NY); Shawn Qian (New York, NY)
Assignee: ATTUNE PHARMACEUTICALS, INC.
C07D401/14A61P7/10A61P17/00A61P37/06C07D401/10C07D401/12C07D413/14C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,981,893
App. No.
15/741,191
Granted
Apr 20, 2021
Kind
B2
Abstract

Provided herein are heterocyclic derivative compounds of Formula (I) and pharmaceutical compositions comprising said compounds. The compounds of Formula (I) are useful for inhibiting plasma kallikrein. Furthermore, the disclosed compounds and compositions are useful for the treatment of diseases wherein the inhibition of plasma kallikrein inhibition has been implicated, such as angioedema and the like.

Claims (17)

1. A compound, or a pharmaceutically acceptable salt thereof, selected from:

N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((6-amino-2-methylpyridin-3-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((3-chloro-6-fluoro-1H-indol-5-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((5-chloro-1H-indazol-3-yl)methyl)-2-((3-chloroquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)-2-((3-methylquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-2-((3-methylquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((6-amino-2-methylpyridin-3-yl)methyl)-2-((3-methylquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((5-chloro-1H-indazol-3-yl)methyl)-2-((3-methylquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((3-chloro-6-fluoro-1H-indol-5-yl)methyl)-2-((3-methylquinolin-6-yl)methyl)pyrimidine-4-carboxamide;

N-((6-amino-2,4-dimethylpyridin-3-yl)methyl)-2-((6-chloroquinolin-3-yl)methyl)pyrimidine-4-carboxamide;

N-((3-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)methyl)-2-((6-chloroquinolin-3-yl)methyl)pyrimidine-4-carboxamide;

N-((6-amino-2-methylpyridin-3-yl)methyl)-2-((6-chloroquinolin-3-yl)methyl)pyrimidine-4-carboxamide;

N-((5-chloro-1H-indazol-3-yl)methyl)-2-((6-chloroquinolin-3-yl)methyl)pyrimidine-4-carboxamide; and

N-((3-chloro-6-fluoro-1H-indol-5-yl)methyl)-2-((6-chloroquinolin-3-yl)methyl)pyrimidine-4-carboxamide.

2. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 10, 2020
From: LIFESCI PHARMACEUTICALS, INC.
To: ATTUNE PHARMACEUTICALS, INC.
Reel/Frame 052073/0760 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2018
From: MCDONALD, ANDREW; QIAN, SHAWN
To: LIFESCI PHARMACEUTICALS, INC.
Reel/Frame 045694/0055 →
Continuity (2)
Provisional Application 62187475 · Jul 1, 2015
Related Publication 20190263783A1 · Aug 29, 2019